

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete If Known

Application Number	10/753,078
Filing Date	January 8, 2004
First Named Inventor	David H. REIFSNYDER
Art Unit	1656
Examiner Name	Schnizer, Holly G.
Attorney Docket Number	012441.00050 (PP-16331.004)

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
HS		US- 4,637,834	01-20-1987	Thurrow	
		US- 4,966,852	10-30-1990	Wun et al.	
		US- 5,051,497	09-24-1991	Fanning et al.	
		US- 5,276,015	01-04-1994	Khouri et al.	
		US- 5,358,708	10-25-1994	Patel	
		US- 5,503,827	04-02-1996	Woog et al.	
		US- 5,466,783	11-14-1995	Wun et al.	
		US- 5,563,123	10-08-1996	Innis et al.	
		US- 5,589,359	12-31-1996	Innis et al.	
		US- 5,824,644	10-20-1998	Abendschein	
		US- 5,885,781	01-05-1999	Johnson et al.	
		US- 5,902,582	08-15-1996	Hung	
		US- 6,063,764	05-16-2000	Creasey et al.	
		US- 6,103,500	08-15-2000	Innis et al.	
HS		US- 6,242,414	06-05-2001	Johnson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
HS		EP 0 473 564 A1	03/04/92	Monsanto Co.		
HS		EP 0 559 632 A2	09/08/93	Monsanto Co.		
HS		WO 93/25230 A1	12/23/1993	G.D. Searle & Co.		
HS		WO 93/24143	12/9/1993	Cetus Oncology Corporation		
HS		WO 96/04378	02/15/1996	Chiron Corporation		
HS		WO 96/01649	01/25/1996	Washington University		
HS		WO 96/40224	12/19/1996	Chiron Corporation		
HS		WO 97/09063	03/13/1997	Chiron Corporation		

Examiner Signature

Date Considered

8-3-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	10/753,078
Filing Date	January 8, 2004
First Named Inventor	David H. REIFSNYDER
Art Unit	1656
Examiner Name	Schnizer, Holly G.
Attorney Docket Number	012441.00050 (PP-16331.004)

Sheet 2 of 6

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
HS		EP 0 414 374 B1	10/08/1997	Smithkline Biologicals S.A.		
		EP 0 755 438 B1	02/14/2001	Amgen Inc.		
		WO 93/18150 A1	09/18/1993	Biocine Sclavo S.P.A.		
		WO 96/01272 A1	01/18/1996	Rican Limited		
		WO 96/01273 A1	01/18/1996	Rican Limited		
		WO 99/57280	11/11/1999	Chiron Corp.		
HS		WO 01/64922 A2	09/07/2001	Chiron SPA		

**Examiner
Signature**

Date
Considered

8-3-06

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/753,078
Filing Date	January 8, 2004
First Named Inventor	David H. REIFSNYDER
Art Unit	1656
Examiner Name	Schnizer, Holly G.
Attorney Docket Number	012441.00050 (PP-16331.004)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HS		Rainer Rudolph, "Successful Protein Folding on an Industrial Scale", Protein Engineering: Principles and Practice, Chapter 10, pps. 283-298 (1996)	
		Rudolph & Lillie, "In Vitro Folding of Inclusion Body Proteins", Folding of Acidic Fibroblast Growth Factor, FASEB J., 10, pps. 49-56	
		Dabora <i>et al.</i> , "Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor", The Journal of Biological Chemistry, Vol. 266, No. 35, pps. 23637-23640 (1991)	
		Bernhard Fisher <i>et al.</i> , "Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed in Escherichia coli as Inclusion Bodies", Biotechnology and Bioengineering, Vol. 41, pps. 3-13 (1993)	
		J. Harenberg, <i>et al.</i> , "Tissue Factor Pathway Inhibitor: Proposed Heparin Recognition Region, Blood Coagulation and Fibrinolysis, Vol. 6, Supp. No. 1, pps. S50-S56 (1995)	
		Mark E. Gustafson <i>et al.</i> , "Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. Coli, Protein Expression and Purification", Vol. 5, pps. 233-241 (1994)	
		Carr, C. <i>et al.</i> , "Recombinant E-Coli-Derived Tissue Factor Pathway Inhibitor Reduces Coagulopathic and Lethal Effects in the Baboon Gram-Negative Model of Septic Shock", Wiley-Liss, Div. John Wiley & Sons, Inc., 605 Third Ave., New York, NY 10158-0012	
		Curless <i>et al.</i> , "Phosphate Glass as a Phosphate Source in High Cell Density Escherichia Coli Fermentations", Biotechnology Progress, vol. 12, pp. 22-25 (1996) XP002238061	
		Malaoui <i>et al.</i> , "Influence of Glucose on Glycerol Metabolism by Wild-Type and Mutant Strains of Clostridium Butyricum E5 grown in Chemostat Culture", Applied Microbiology and Biotechnology, vol. 55, December 2000 (2000-12), pp. 226-233, XP002237996	
HS		Vagabov <i>et al.</i> , "Dependence of Inorganic Polyphosphate Chain Length on the Orthophosphate Content in the Culture Medium of the Yeast Saccharomyces Cerevisiae", Biochemistry (Moscow), vol. 65, 2000, pp. 349-354, XP002237997	

Examiner
SignatureDate
Considered

8-3-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/753,078
		Filing Date	January 8, 2004
		First Named Inventor	David H. REIFSNYDER
		Art Unit	1656
		Examiner Name	Schnizer, Holly G.
Sheet	4	of	6
		Attorney Docket Number	012441.00050 (PP-16331.004)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS		Albertson <i>et al.</i> , "Growth and Survival of Helicobacter Pylori in Defined Medium and Susceptibility to Brij 78", <i>Journal of Clinical Microbiology</i> , vol. 36, 1998, pp. 1232-1235, XP002238062	
		Bauer <i>et al.</i> , "Improved Expression of Human Interleukin-2 in High-Cell-Density-Density Fermentor Cultures of Escherichia Coli K-12 by a Phosphotransacetylase Mutant", 1990, <i>Appl. Environ. Microbiol.</i> , 56: 1296-1302	
		Bonsignore <i>et al.</i> , "Development of a Chemically Defined Medium for Bacterial Biotin Production", 1989, <i>Abstr. Pap. Am. Chem. Soc.</i> 198 Meet, MBTD 199	
		Box & Wilson, "On the Experimental Attainment of Optimum Conditions", 1951, <i>J. Roy. Statist. Soc.</i> , B13: 1-45	
		Chalmers <i>et al.</i> , "Effects of Temperature on Escherichia Coli Overproducing β -Lactamase or Human Epidermal Growth Factor", 1990, <i>Appl. Environ. Microbiol.</i> , 56: 104-111	
		Evans, D.J. <i>et al.</i> , "Identification of Four New Prokaryotic Bacterioferritins, from Helicobacter Pylori, Anabaena Variabilis, Bacillus Subtilis and Treponema Pallidum, by Analysis of Gene Sequences", 1995, <i>Gene</i> , 153: 123-127	
		De Vuyst, L., "Nutritional Factors Affecting Nisin Production by Lactococcus Lactus Subsp. Lactis NIZO 22186 in a Synthetic Medium", 1995, <i>J. Appl. Bacteriol.</i> , 78: 28-33	
		Galindo <i>et al.</i> , "Maximizing the Expression of Recombinant Proteins in Escherichia Coli by Manipulation of Culture Conditions", 1990, <i>J. Ferm. Bioeng.</i> , 69: 159-165	
		Konstantinov <i>et al.</i> , "Physiologically Motivated Strategies for Control of the Fed-Batch Cultivation of Recombinant Escherichia Coli for Phenylalanine Production", 1991, <i>J. Ferm. Bioeng.</i> , 71: 350-355	
		Kopetzki <i>et al.</i> , "Control of Formation of Active Soluble or Inactive Insoluble Baker's Yeast α -Glucosidase PI in Escherichia Coli by Induction and Growth Conditions", 1989, <i>Mol. Gen. Genet.</i> , 216: 149-155	
AS		Lee & Lee, "Enhanced Production of Poly(3-hydroxybutyrate) by Filamentation-Suppressed Recombinant Escherichia Coli in a Defined Medium", 1996, <i>Journal of Environmental Polymer Degradation</i> , 4(2): 131-134	

Examiner Signature		Date Considered	8-3-06
--------------------	--	-----------------	--------



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/753,078
		Filing Date	January 8, 2004
		First Named Inventor	David H. REIFSNYDER
		Art Unit	1656
		Examiner Name	Schnizer, Holly G.
(Use as many sheets as necessary)		Attorney Docket Number	012441.00050 (PP-16331.004)
Sheet	5	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Luli & Strohl., "Comparison of Growth, Acetate Production, and Acetate Inhibition of Escherichia Coli Strains in Batch and Fed-Batch Fermentations", 1990, <i>Appl. Environ. Microbiol.</i> , 56: 640-645	
		MacDonald & Neway, "Effects of Medium Quality on the Expression of Human Interleukin-2 at High Cell Density in Fermentor Cultures of Escherichia Coli K-12", 1990, <i>Appl. Environ. Microbiol.</i> , 56: 640-645	
		Manetti, R. <i>et al.</i> , "Helicobacter Pylori Cytotoxin: Importance of Native Conformation for Induction of Neutralizing Antibodies", 1995, <i>Infect. Immun.</i> , 63: 4476-4480	
		Okita <i>et al.</i> , "Effect of Induction Temperature on the Production of Malaria Antigens in Recombinant E. Coli", 1989, <i>Biotechnol. Bioeng.</i> , 34: 854-862	
		Park & Ryu, "Effect of Operating Parameters on Specific Production Rate of a Cloned-Gene Product and Performance of Recombinant Fermentation Process" 1990, <i>Biotechnol. Bioeng.</i> , 35: 287-295	
		Rappuoli <i>et al.</i> , "Development of a Vaccine Against Helicobacter Pylori: A Short Overview", 1993, <i>European Journal of Gastroenterology and Hepatology of Helicobacter Pylori Infection</i> , Proceedings of an Interdisciplinary Meeting (Geneva, June 18-19, 1993) J.J. Misiewicz, Ed. (CS Current Science) pp. S76-S78	
		Rappuoli, R., "Toxin Inactivation and antigen Stabilization: Two Different Uses of Formaldehyde", 1994, <i>Vaccine</i> , 12(7): 579-581	
		Rinas <i>et al.</i> , "Glucose as a Ssubstrate in Recombinant Strain Fermentation Technology", 1989, <i>Appl. Microbiol. Biotechnol.</i> , 31: 163-167	
		Stephenns, J., "Development and Production Aspects of a Recombinant Yeast-Derived Hepatitis B Vaccine", 1990, <i>Vaccine</i> , 8: S69-S73	

Examiner Signature		Date Considered	8-3-06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/753,078
		<i>Filing Date</i>	January 8, 2004
		<i>First Named Inventor</i>	David H. REIFSNYDER
		<i>Art Unit</i>	1656
		<i>Examiner Name</i>	Schnizer, Holly G.
(Use as many sheets as necessary)		<i>Attorney Docket Number</i>	012441.00050 (PP-16331.004)
Sheet	6	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HS		Stratakalis <i>et al.</i> , "Development of an Escherichia Coli Culture and Fermentation Process for PL-Regulated Expression of HIV-1 Protease," 1991, <i>Abstr. Gen. Meet. Am. Soc. Microbiol.</i> , 91 Meet, 190	
		Zhang <i>et al.</i> , "Process Characterization Studies to Facilitate Validation of a Recombinant Protein Fermentation," 1998, in: Kelley & Ramelmeler (eds) <i>ACS Symposium Ser 698</i> : 12-27	
		Zhang & Greasham, "Chemically Defined Media for Commercial Fermentations," 1999, <i>Appl. Microbiol. Biotechnol.</i> , 51:407-421	
		Moser, A. (1985) Chapters 14-16 of <i>Fundamentals of Biochemical Engineering</i> (ed. Brauer)	
		Carr <i>et al.</i> , <i>Circulatory Shock</i> , 44(3): 126-37 (1994)	
HS		International Search Report in Counterpart International Application PCT/US04/00234	

Examiner Signature		Date Considered	8-3-06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.